ATE497002T1 - Gef-h1b: biomarker, komplexe, assays und therapeutische verwendungen davon - Google Patents
Gef-h1b: biomarker, komplexe, assays und therapeutische verwendungen davonInfo
- Publication number
- ATE497002T1 ATE497002T1 AT03763085T AT03763085T ATE497002T1 AT E497002 T1 ATE497002 T1 AT E497002T1 AT 03763085 T AT03763085 T AT 03763085T AT 03763085 T AT03763085 T AT 03763085T AT E497002 T1 ATE497002 T1 AT E497002T1
- Authority
- AT
- Austria
- Prior art keywords
- gef
- biomarrkers
- assayes
- complexes
- therapeutic uses
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 abstract 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 abstract 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39360002P | 2002-07-05 | 2002-07-05 | |
| US46005303P | 2003-04-04 | 2003-04-04 | |
| PCT/US2003/020743 WO2004005529A2 (en) | 2002-07-05 | 2003-07-02 | GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE497002T1 true ATE497002T1 (de) | 2011-02-15 |
Family
ID=30118381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03763085T ATE497002T1 (de) | 2002-07-05 | 2003-07-02 | Gef-h1b: biomarker, komplexe, assays und therapeutische verwendungen davon |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7439329B2 (de) |
| EP (1) | EP1539956B1 (de) |
| JP (1) | JP4522855B2 (de) |
| AT (1) | ATE497002T1 (de) |
| AU (1) | AU2003256356A1 (de) |
| DE (1) | DE60335883D1 (de) |
| DK (1) | DK1539956T3 (de) |
| PT (1) | PT1539956E (de) |
| WO (1) | WO2004005529A2 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861442B1 (en) * | 1998-12-30 | 2005-03-01 | Sugen, Inc. | PYK2 and inflammation |
| ES2397637T3 (es) | 2006-11-10 | 2013-03-08 | Massachusetts Institute Of Technology | Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939224A (en) * | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
| DE4412174A1 (de) * | 1994-04-08 | 1995-10-19 | Schramm Wolfgang Prof Dr | Peptide, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5863532A (en) * | 1996-03-14 | 1999-01-26 | The Regents Of The University Of California | Compositions and methods comprising cytostatic protein kinase |
| DK1073723T3 (da) * | 1998-04-14 | 2006-01-02 | Sugen Inc | STE20-relaterede proteinkinaser |
| US6013500A (en) * | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
| JP2003523733A (ja) * | 1999-10-29 | 2003-08-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | １０個のヒト分泌タンパク質 |
| US20050100554A1 (en) * | 2002-02-14 | 2005-05-12 | Amanda Jackson | Complexes and methods of using same |
-
2003
- 2003-07-02 JP JP2004519732A patent/JP4522855B2/ja not_active Expired - Fee Related
- 2003-07-02 AU AU2003256356A patent/AU2003256356A1/en not_active Abandoned
- 2003-07-02 DK DK03763085.2T patent/DK1539956T3/da active
- 2003-07-02 US US10/611,671 patent/US7439329B2/en not_active Expired - Fee Related
- 2003-07-02 EP EP03763085A patent/EP1539956B1/de not_active Expired - Lifetime
- 2003-07-02 PT PT03763085T patent/PT1539956E/pt unknown
- 2003-07-02 AT AT03763085T patent/ATE497002T1/de active
- 2003-07-02 WO PCT/US2003/020743 patent/WO2004005529A2/en not_active Ceased
- 2003-07-02 DE DE60335883T patent/DE60335883D1/de not_active Expired - Lifetime
-
2008
- 2008-09-11 US US12/232,134 patent/US7871786B2/en not_active Expired - Fee Related
-
2010
- 2010-11-30 US US12/957,212 patent/US20110159532A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005532062A (ja) | 2005-10-27 |
| WO2004005529A3 (en) | 2004-07-22 |
| EP1539956B1 (de) | 2011-01-26 |
| WO2004005529A2 (en) | 2004-01-15 |
| EP1539956A2 (de) | 2005-06-15 |
| AU2003256356A1 (en) | 2004-01-23 |
| DK1539956T3 (da) | 2011-03-28 |
| EP1539956A4 (de) | 2006-09-06 |
| AU2003256356A8 (en) | 2004-01-23 |
| DE60335883D1 (de) | 2011-03-10 |
| JP4522855B2 (ja) | 2010-08-11 |
| US7871786B2 (en) | 2011-01-18 |
| US20090130695A1 (en) | 2009-05-21 |
| US20110159532A1 (en) | 2011-06-30 |
| PT1539956E (pt) | 2011-03-16 |
| US20040091907A1 (en) | 2004-05-13 |
| US7439329B2 (en) | 2008-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moraes et al. | Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2–hUbc13 | |
| BRPI0607306A2 (pt) | derivados de quinoxalina como agentes anti-tumor | |
| Chen et al. | Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein | |
| MX2007010272A (es) | Inhibidores de moleculas pequenas de mdm2 y usos de los mismos. | |
| BRPI0514537A (pt) | compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase | |
| WO2005084109A3 (en) | Cancer specific gene mh15 | |
| ATE373239T1 (de) | Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs | |
| NO20020637L (no) | Bestemmelse av hematologisk toksisitet av medikamenter forut for radioimmunoterapi | |
| BRPI0513915A (pt) | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase | |
| ATE501267T1 (de) | Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs | |
| Liu et al. | Structure‐based discovery of new selective small‐molecule sirtuin 5 inhibitors | |
| Gao et al. | Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening | |
| TR200402517T2 (tr) | HBV ilaç direnci tespit metotları | |
| ATE497002T1 (de) | Gef-h1b: biomarker, komplexe, assays und therapeutische verwendungen davon | |
| DE602006015686D1 (de) | Als agonisten des gpr38-rezeptors geeignete biarylverbindungen | |
| ATE484747T1 (de) | Teststück fur proteinassay | |
| Tu et al. | Discovery of lipoic acid-4-phenyl-1 H-pyrazole hybrids as novel bifunctional ROCK inhibitors with antioxidant activity | |
| ATE433115T1 (de) | Timp-2 als ziel/marker des versagens von beta- zellen | |
| UA84020C2 (ru) | Ингибитор проникновения вируса вил | |
| DE50207305D1 (de) | Quantitative diagnostische analyse der prädisposition für hypertonie | |
| ATE390427T1 (de) | Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande | |
| DK1948689T3 (da) | Højaktivitetsvækstfaktormutanter | |
| GB0514913D0 (en) | Polymorphism | |
| Hanzl et al. | Charting functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders | |
| DE602006020467D1 (de) | Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1539956 Country of ref document: EP |